Table 2.
Neurocognitive Outcomes, Comparing the 3 Arms, Assessed Longitudinally Over the Course of Study Participation
| Outcome Variable | Study Arm | Univariable Analysis | Multivariable Analysisa | ||
|---|---|---|---|---|---|
| Estimated Difference (95% CI) | P Value | Estimated Difference (95% CI) | P-Value | ||
| Visual reception | R15HZE | Ref | Ref | ||
| R30HZE | 1.96 (–5.65 to 9.57) | .61 | 3.56 (–2.72 to 9.83) | .27 | |
| R30HZL | 0.45 (–7.13 to 8.03) | .91 | –2.83 (–9.77 to 4.10) | .42 | |
| Fine motor | R15HZE | Ref | Ref | ||
| R30HZE | 10.7 (3.19–18.28) | .005 | 12.0 (5.46–18.5) | <.01 | |
| R30HZL | 5.20 (–2.39 to 12.8) | .18 | 2.40 (–4.82 to 9.62) | .52 | |
| Receptive language | R15HZE | Ref | Ref | ||
| R30HZE | 11.78 (3.61–20.0) | .005 | 12.2 (5.87–18.5) | <.01 | |
| R30HZL | 4.80 (–3.36 to 13.0) | .25 | 1.30 (–5.68 to 8.28) | .72 | |
| Expressive language | R15HZE | Ref | .03 | Ref | |
| R30HZE | 13.2 (1.4–24.9) | .22 | 14.9 (4.45–25.28) | .01 | |
| R30HZL | 7.2 (–4.4 to 18.8) | 2.64 (–8.45 to 13.7) | .64 | ||
| Gross motor | R15HZE | Ref | .24 | Ref | |
| R30HZE | 5.02 (–3.37 to 13.41) | 4.15 (–1.20 to 9.50) | .13 | ||
| R30HZL | 16.02 (7.37–25.54) | <.001 | 7.20 (–.31 to 14.71) | .06 | |
Abbreviations: CI, confidence interval; R15HZE, standard-dose rifampicin (15 mg/kg/day), isoniazid, pyrazinamide, ethambutol; R30HZE, high-dose rifampicin (30 mg/kg/day), isoniazid, pyrazinamide, ethambutol; R30HZL, high-dose rifampicin (30 mg/kg/day), isoniazid, pyrazinamide, levofloxacin.
Adjusted for age, sex, and baseline Modified Rankin Scale.